Diverse Regulatory Cell Populations in Antibody Mediated Rejection.
- 1Department of Microbiology and Immunology, Columbia University, New York City, NY USA.
- 2Florida Research and Innovation Center, Cleveland Clinic Research, Port St. Lucie, FL USA.
Abstract
Antibody-mediated rejection (ABMR) is a leading cause of late graft loss, and current therapies act almost exclusively on the effector arm of the alloimmune response. This review examines three classes of regulatory cell from innate and adaptive lineages and the stages of the ABMR response at which each acts, in order to assess their potential as therapeutic targets. CD4⁺ Tregs constrain alloimmune priming through CTLA4 dependent costimulatory blockade, cytokine-mediated suppression, and competition for IL-2. CXCR5⁺CD8⁺ antibody-suppressor cells directly eliminate donor-reactive IgG⁺ B cells in murine models. T follicular regulatory (Tfr) cells restrain germinal center reactions and alloantibody generation, and their loss produces enhanced, more pathogenic donor-specific antibody (DSA). Notably, Tfr regulation is initiated early in T-B interactions, Tfr expansion physiologically lags that of Tfh cells, and Tfr numbers are reduced in chronic ABMR. Regulatory B cells and myeloid-derived suppressor cells remain comparatively unexplored in ABMR, and the latter carry a risk of profibrotic differentiation under chronic inflammatory conditions. Regulatory cell populations act predominantly during the early phases of the alloimmune response. Their therapeutic utility in ABMR is therefore likely to be constrained by timing, and to lie in the prevention of de novo DSA rather than the reversal of established rejection.
Related
- CD4+CD25+ regulatory T cells circumstantially initiate transplant rejection through CXCL15/neutrophil axis
- A synthetic phageome reveals widespread and diverse human antibody responses to bacteriophages
- Designed nanofiber immunogens prime antibody responsesto diverse conformations of the HIV-1 fusion peptide
- HLA-DQ molecular mismatch predicts acute rejection and donor-specific antibody development after pediatric liver transplantation
- Overview of Regulatory Guidelines Related to Methods and Models for Small Populations
BibTeX
@article{karulina2026diverse,
title = {{Diverse Regulatory Cell Populations in Antibody Mediated Rejection.}},
author = {Eugenia Karulina and Michael Nicosia},
journal = {Current transplantation reports},
year = {2026},
month = nov,
doi = {10.1007/s40472-026-00537-4},
url = {https://europepmc.org/article/MED/42999501},
note = {CC BY},
}
RIS
TY - JOUR
TI - Diverse Regulatory Cell Populations in Antibody Mediated Rejection.
AU - Eugenia Karulina
AU - Michael Nicosia
PY - 2026
DA - 2026/11/06
JO - Current transplantation reports
DO - 10.1007/s40472-026-00537-4
UR - https://europepmc.org/article/MED/42999501
AB - Antibody-mediated rejection (ABMR) is a leading cause of late graft loss, and current therapies act almost exclusively on the effector arm of the alloimmune response. This review examines three classes of regulatory cell from innate and adaptive lineages and the stages of the ABMR response at which each acts, in order to assess their potential as therapeutic targets. CD4⁺ Tregs constrain alloimmune priming through CTLA4 dependent costimulatory blockade, cytokine-mediated suppression, and competition for IL-2. CXCR5⁺CD8⁺ antibody-suppressor cells directly eliminate donor-reactive IgG⁺ B cells in murine models. T follicular regulatory (Tfr) cells restrain germinal center reactions and alloantibody generation, and their loss produces enhanced, more pathogenic donor-specific antibody (DSA). Notably, Tfr regulation is initiated early in T-B interactions, Tfr expansion physiologically lags that of Tfh cells, and Tfr numbers are reduced in chronic ABMR. Regulatory B cells and myeloid-derived suppressor cells remain comparatively unexplored in ABMR, and the latter carry a risk of profibrotic differentiation under chronic inflammatory conditions. Regulatory cell populations act predominantly during the early phases of the alloimmune response. Their therapeutic utility in ABMR is therefore likely to be constrained by timing, and to lie in the prevention of de novo DSA rather than the reversal of established rejection.
SN - 2196-3029
ER -